CONNECT WITH US
Web3 & Blockchain

Web3 & Blockchain

MRNA Price Prediction: Price holds above short-term averages as resistance tightens

Blockchain.News logo

Published on

Add as a preferred source on Google
MRNA Price Prediction: Price holds above short-term averages as resistance tightens

Moderna Tokenized Stock (MRNA) was last quoted at $256.84, up 7.72% over 24 hours, with the move taking price above the 7-, 20-, and 50-day moving averages. Goldman Sachs reiterated a Neutral ratin...

Market analysis includes conditional scenarios, not assured price outcomes or investment advice. Check the data, assumptions and dates cited.

MRNA was last quoted at $256.84 on Binance futures, up 7.72% over 24 hours, with a reported intraday range of $225.81 to $275.21 and 24-hour volume of $82.3 million. The price is above the supplied 7-day, 20-day, and 50-day moving averages, which shows that the latest advance has already cleared the shorter trend layers in the provided data.

Goldman Sachs reiterated a Neutral rating on Moderna on November 3, 2026, and maintained a $137 price target, reported by Investing.com. That is a separate analyst reference from the Binance futures instrument and should not be treated as a short-term trading level for the futures quote.

The momentum stack is constructive but not cleanly extended. Daily RSI at 63.64 is in neutral territory, while MACD at 11.5298 matches the signal line and leaves the histogram at 0.0000, so the trend is positive without showing expansion in the gap between MACD and signal. Stochastic %K at 81.56 and %B at 0.9194 place price close to the upper Bollinger band at $263.25, which is consistent with a market pressing into overhead supply rather than moving through open air.

The moving averages reinforce that structure. 03. 50 indicates that the current session still carries wide enough swings to matter for risk control.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.